GluN2B-Mediated Microglial Activation and Tau Propagation

Target: GRIN2B Composite Score: 0.565 Price: $0.58▲4.6% Citation Quality: Pending neuroscience Status: proposed Variant of GluN2B-Mediated Thalamocortical Control of Glympha

☰ Compare ⚔ Duel ⚛ Collideinteract with this hypothesis

📄 Export → LaTeX

Select venue

arXiv Preprint NeurIPS Nature Methods PLOS ONE

🌐 Open in Overleaf →

📖 Export BibTeX

🔬 Microglial Biology 🧠 Neurodegeneration 🔥 Neuroinflammation 🔴 Alzheimer's Disease

✓ All Quality Gates Passed

Evidence Strength Pending (0%)

Citations

Debates

Supporting

Opposing

Quality Report Card click to collapse

C+

Composite: 0.565

Top 53% of 1875 hypotheses

T2 Supported

Literature-backed with debate validation

Needs convergence ≥0.40 (current: 0.00) for Established

B Mech. Plausibility 15% 0.60 Top 57%

B+ Evidence Strength 15% 0.71 Top 18%

C Novelty 12% 0.45 Top 92%

F Feasibility 12% 0.00 Top 50%

F Impact 12% 0.00 Top 50%

C Druggability 10% 0.41 Top 80%

C+ Safety Profile 8% 0.50 Top 57%

C+ Competition 6% 0.53 Top 74%

A+ Data Availability 5% 0.93 Top 15%

D Reproducibility 5% 0.25 Top 94%

Evidence

3 supporting | 3 opposing

Citation quality: 75%

Debates

18 sessions B

Avg quality: 0.61

Convergence

0.00 F 8 related hypothesis share this target

From Analysis:

Circuit-level neural dynamics in neurodegeneration

Analyze circuit-level changes in neurodegeneration using Allen Institute Neural Dynamics data. Focus on: (1) hippocampal circuit disruption, (2) cortical dynamics alterations, (3) sensory processing changes. Identify circuit-based therapeutic targets connecting genes, proteins, and brain regions to neurodegeneration phenotypes.

→ View full analysis & debate transcript

Description

Mechanistic Overview

...

Mechanistic Overview

GluN2B-Mediated Microglial Activation and Tau Propagation starts from the claim that modulating GRIN2B within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "## Mechanistic Overview GluN2B-Mediated Microglial Activation and Tau Propagation starts from the claim that modulating GRIN2B within the disease context of neuroscience can redirect a disease-relevant process. The original description reads: "This hypothesis proposes that GluN2B-containing NMDA receptors in thalamocortical circuits regulate tau pathology through direct control of microglial activation states and trans-synaptic tau propagation rather than glymphatic clearance mechanisms. The mechanistic framework centers on thalamocortical gamma oscillations driving glutamate release patterns that activate extrasynaptic GluN2B receptors on microglia, maintaining them in a homeostatic surveillance state characterized by enhanced phagocytic capacity and anti-inflammatory cytokine production. When thalamocortical synchrony is disrupted due to GluN2B dysfunction in neurodegeneration, the loss of coordinated glutamate signaling shifts microglia toward a pro-inflammatory phenotype with reduced tau uptake capacity and increased secretion of inflammatory mediators that promote tau hyperphosphorylation. This creates a pathological cascade where dysregulated oscillatory activity leads to microglial dysfunction, impaired tau internalization and degradation, and enhanced release of pathological tau seeds that propagate along thalamocortical projections to cortical regions. The disrupted network activity also facilitates activity-dependent tau release at synapses, creating hotspots of tau accumulation at thalamocortical terminals. The hypothesis predicts that selective enhancement of GluN2B-mediated thalamocortical synchrony will restore homeostatic microglial function, reduce neuroinflammation, and limit tau propagation through improved microglial clearance and reduced synaptic tau release. This mechanism explains the spatial pattern of tau spreading from thalamic nuclei to connected cortical areas and suggests that GluN2B-targeted interventions could simultaneously address network dysfunction and tau propagation in tauopathies." Framed more explicitly, the hypothesis centers GRIN2B within the broader disease setting of neuroscience. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence. The decision-relevant question is whether modulating GRIN2B or the surrounding pathway space around thalamocortical-microglial axis can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win. SciDEX scoring currently records confidence 0.71, and mechanistic plausibility 0.75. ## Molecular and Cellular Rationale The nominated target genes are `GRIN2B` and the pathway label is `thalamocortical-microglial axis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair. Gene-expression context on the row adds an important constraint: Gene Expression Context GRIN2B: - GRIN2B (Glutamate Ionotropic Receptor NMDA Type Subunit 2B, also known as GluN2B/NR2B) is a subunit of NMDA receptors that determines receptor kinetics, Mg2+ sensitivity, and downstream signaling specificity. GRIN2B-containing NMDA receptors are critical for synaptic plasticity, learning, and memory. Allen Human Brain Atlas shows high expression in hippocampus, cortex, and thalamus, peaking during early development. In AD, GRIN2B expression is reduced in hippocampus and cortex, contributing to impaired NMDA-dependent LTP and cognitive decline. Extrasynaptic GRIN2B-NMDAR activation promotes excitotoxicity and amyloid-beta oligomer signaling. - Datasets: Allen Human Brain Atlas, SEA-AD snRNA-seq, GTEx Brain v8, Mathys et al. 2019 - Expression Pattern: Neuron-specific; highest in hippocampal pyramidal neurons and cortical layers II-III; developmental peak then sustained adult expression; synaptic and extrasynaptic pools Cell Types: - Excitatory pyramidal neurons (highest) - Inhibitory interneurons (moderate) - Hippocampal CA1 pyramidal neurons (very high) - Not expressed in glia Key Findings: 1. GRIN2B mRNA reduced 30-50% in AD hippocampus vs age-matched controls (SEA-AD) 2. Extrasynaptic GRIN2B-NMDAR activation by Abeta oligomers triggers calcineurin-dependent synaptic depression 3. GRIN2B/GRIN2A ratio decreases with age and further in AD, shifting NMDA signaling toward faster kinetics 4. Memantine selectively blocks extrasynaptic NMDARs, partially rescuing AD cognitive deficits 5. GRIN2B dephosphorylation at Tyr1472 reduces synaptic NMDAR surface expression in AD Regional Distribution: - Highest: Hippocampus CA1-CA3, Prefrontal Cortex Layers II-III, Entorhinal Cortex - Moderate: Temporal Cortex, Cingulate Cortex, Thalamus - Lowest: Cerebellum (GRIN2A dominant), Brainstem, Spinal Cord This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance. Within neuroscience, the working model should be treated as a circuit of stress propagation. Perturbation of GRIN2B or thalamocortical-microglial axis is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states. ## Evidence Supporting the Hypothesis 1. Thalamocortical circuit integrity differentiates normal aging from mild cognitive impairment, with decreased neural complexity and increased synchronization being hallmarks of dysfunction. Identifier 19449329. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 2. NMDA receptor function is required for Aβ-induced synaptic depression, indicating these receptors are key mediators of circuit dysfunction. Identifier 23431156. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 3. GluN2B subunits play distinct roles in visual cortical plasticity. Identifier 26282667. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 4. Inhibition of GluN2B-containing N-methyl-D-aspartate receptors by radiprodil. Identifier 40994429. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 5. Cognitive loss after brain trauma results from sex-specific activation of synaptic pruning processes. Identifier 40796363. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. 6. Aberrant mRNA splicing and impaired hippocampal neurogenesis in Grin2b mutant mice. Identifier 41675057. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan. ## Contradictory Evidence, Caveats, and Failure Modes 1. NMDA receptors mediate synaptic depression in amyloid models, suggesting NMDA enhancement could worsen dysfunction rather than improve it. Identifier 30352630. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 2. Epigenetics in Learning and Memory. Identifier 39820860. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. 3. Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Identifier 37369776. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients. ## Clinical and Translational Relevance From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.56`, debate count `3`, citations `19`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions. 1. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 2. Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. 3. Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone. For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy. ## Experimental Predictions and Validation Strategy First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates GRIN2B in a model matched to neuroscience. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "GluN2B-Mediated Microglial Activation and Tau Propagation". Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker. Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing. Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue. ## Decision-Oriented Summary In summary, the operational claim is that targeting GRIN2B within the disease frame of neuroscience can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence." Framed more explicitly, the hypothesis centers GRIN2B within the broader disease setting of neuroscience. The row currently records status `proposed`, origin `gap_debate`, and mechanism category `unspecified`. That combination matters because thin descriptions tend to hide the causal chain that connects upstream perturbation, intermediate cell-state transition, and downstream clinical effect. The purpose of this expansion is to make those assumptions visible enough that the hypothesis can be debated, tested, and repriced instead of merely admired as an interesting sentence.
The decision-relevant question is whether modulating GRIN2B or the surrounding pathway space around thalamocortical-microglial axis can redirect a disease process rather than merely decorate it with a biomarker change. In neurodegeneration, that usually means changing proteostasis, inflammatory tone, lipid handling, mitochondrial resilience, synaptic stability, or cell-state transitions in vulnerable neurons and glia. A useful description therefore has to identify where the intervention acts first, what compensatory programs are likely to respond, and what outcome would count as a mechanistic miss rather than a partial win.
SciDEX scoring currently records confidence 0.71, and mechanistic plausibility 0.75.

Molecular and Cellular Rationale

The nominated target genes are `GRIN2B` and the pathway label is `thalamocortical-microglial axis`. Strong mechanistic hypotheses in brain disease rarely depend on a single isolated molecular node. Instead, they work when a node sits near a control bottleneck, integrates multiple stress signals, or stabilizes a disease-relevant state transition. That is the standard this hypothesis should be held to. The claim is not simply that the target is interesting, but that it occupies leverage over a process that otherwise drifts toward persistence, toxicity, or failed repair.
Gene-expression context on the row adds an important constraint: Gene Expression Context GRIN2B: - GRIN2B (Glutamate Ionotropic Receptor NMDA Type Subunit 2B, also known as GluN2B/NR2B) is a subunit of NMDA receptors that determines receptor kinetics, Mg2+ sensitivity, and downstream signaling specificity. GRIN2B-containing NMDA receptors are critical for synaptic plasticity, learning, and memory. Allen Human Brain Atlas shows high expression in hippocampus, cortex, and thalamus, peaking during early development. In AD, GRIN2B expression is reduced in hippocampus and cortex, contributing to impaired NMDA-dependent LTP and cognitive decline. Extrasynaptic GRIN2B-NMDAR activation promotes excitotoxicity and amyloid-beta oligomer signaling. - Datasets: Allen Human Brain Atlas, SEA-AD snRNA-seq, GTEx Brain v8, Mathys et al. 2019 - Expression Pattern: Neuron-specific; highest in hippocampal pyramidal neurons and cortical layers II-III; developmental peak then sustained adult expression; synaptic and extrasynaptic pools Cell Types: - Excitatory pyramidal neurons (highest) - Inhibitory interneurons (moderate) - Hippocampal CA1 pyramidal neurons (very high) - Not expressed in glia Key Findings: 1. GRIN2B mRNA reduced 30-50% in AD hippocampus vs age-matched controls (SEA-AD) 2. Extrasynaptic GRIN2B-NMDAR activation by Abeta oligomers triggers calcineurin-dependent synaptic depression 3. GRIN2B/GRIN2A ratio decreases with age and further in AD, shifting NMDA signaling toward faster kinetics 4. Memantine selectively blocks extrasynaptic NMDARs, partially rescuing AD cognitive deficits 5. GRIN2B dephosphorylation at Tyr1472 reduces synaptic NMDAR surface expression in AD Regional Distribution: - Highest: Hippocampus CA1-CA3, Prefrontal Cortex Layers II-III, Entorhinal Cortex - Moderate: Temporal Cortex, Cingulate Cortex, Thalamus - Lowest: Cerebellum (GRIN2A dominant), Brainstem, Spinal Cord This matters because expression and cell-state data narrow the plausible mechanism space. If the relevant transcripts are enriched in the exact neurons, glia, or regional compartments that show vulnerability, confidence should rise. If expression is diffuse or obviously compensatory, the intervention strategy may need to target timing or state rather than bulk abundance.
Within neuroscience, the working model should be treated as a circuit of stress propagation. Perturbation of GRIN2B or thalamocortical-microglial axis is unlikely to matter in isolation. Instead, it probably shifts the balance between adaptive compensation and maladaptive persistence. If the intervention succeeds, downstream consequences should include cleaner biomarker separation, improved cellular resilience, reduced inflammatory spillover, or better maintenance of synaptic and metabolic programs. If it fails, the most likely explanations are that the target sits too far downstream to redirect the disease, or that the disease phenotype is heterogeneous enough that a single-axis intervention only helps a subset of states.

Evidence Supporting the Hypothesis

Thalamocortical circuit integrity differentiates normal aging from mild cognitive impairment, with decreased neural complexity and increased synchronization being hallmarks of dysfunction. Identifier 19449329. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

NMDA receptor function is required for Aβ-induced synaptic depression, indicating these receptors are key mediators of circuit dysfunction. Identifier 23431156. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

GluN2B subunits play distinct roles in visual cortical plasticity. Identifier 26282667. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Inhibition of GluN2B-containing N-methyl-D-aspartate receptors by radiprodil. Identifier 40994429. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Cognitive loss after brain trauma results from sex-specific activation of synaptic pruning processes. Identifier 40796363. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Aberrant mRNA splicing and impaired hippocampal neurogenesis in Grin2b mutant mice. Identifier 41675057. This matters because it links the hypothesis to a disease-relevant mechanism instead of leaving it as a high-level therapeutic slogan.

Contradictory Evidence, Caveats, and Failure Modes

NMDA receptors mediate synaptic depression in amyloid models, suggesting NMDA enhancement could worsen dysfunction rather than improve it. Identifier 30352630. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Epigenetics in Learning and Memory. Identifier 39820860. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry. Identifier 37369776. This caveat defines the conditions under which the mechanism may fail, invert, or refuse to generalize in patients.

Clinical and Translational Relevance

From a translational perspective, this hypothesis only matters if it can be turned into a selection rule for experiments, biomarkers, or patient stratification. The row currently records market price `0.56`, debate count `3`, citations `19`, predictions `0`, and falsifiability flag `1`. Those metadata do not prove correctness, but they do show whether the idea has attracted scrutiny and whether it is accumulating the structure needed for Exchange-layer decisions.

Trial context: COMPLETED. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

Trial context: ACTIVE_NOT_RECRUITING. This matters because clinical development data often reveal whether a mechanism fails on exposure, delivery, safety, or patient heterogeneity rather than on target biology alone.

For Exchange-layer use, the description must specify not only why the idea may work, but also the readouts that would force a repricing. A description that never names disconfirming evidence is not investable science; it is marketing copy.

Experimental Predictions and Validation Strategy

First, the hypothesis should be decomposed into a perturbation experiment that directly manipulates GRIN2B in a model matched to neuroscience. The key readout should include pathway markers, cell-state markers, and at least one phenotype that maps onto "GluN2B-Mediated Microglial Activation and Tau Propagation".
Second, the study design should include a rescue arm. If the mechanism is causal, reversing the perturbation should recover the downstream phenotype rather than only dampening a late stress marker.
Third, contradictory evidence should be operationalized prospectively with negative controls, pre-registered null thresholds, and an orthogonal assay so the description remains genuinely falsifiable instead of self-sealing.
Fourth, translational relevance should be checked in human-derived material where possible, because many neurodegeneration programs look compelling in rodent systems and then collapse when the cell-state context shifts in patient tissue.

Decision-Oriented Summary

In summary, the operational claim is that targeting GRIN2B within the disease frame of neuroscience can produce a measurable change in mechanism rather than only a cosmetic change in a terminal biomarker. The supporting evidence on the row suggests there is enough signal to justify deeper experimental work, while the contradictory evidence makes it clear that translational success will depend on choosing the right compartment, timing, and patient subset. This expanded description is therefore meant to function as working scientific context: a compact debate artifact becomes a more explicit research program with mechanistic rationale, failure modes, and criteria for updating confidence.

No AI visual card yet

Curated Mechanism Pathway

Curated pathway diagram from expert analysis

graph TD
    A["GluN2B NMDA Receptor
Extrasynaptic Expression"] --> B["Calcium Influx
Ca2+ Permeable Channel"]
    B --> C["CaMKII Activation
Calcium-Dependent Kinase"]
    C --> D["CREB Phosphorylation
Transcription Factor"]
    D --> E["Synaptic Plasticity Genes
LTP Enhancement"]
    
    A --> F["Thalamic Relay Neurons
VB and VPM Nuclei"]
    F --> G["Cortical Layer IV
Sensory Input Processing"]
    G --> H["Pyramidal Neurons
Layer V Output"]
    
    A --> I["Gamma Oscillations
40-100 Hz Frequency"]
    I --> J["Theta Oscillations
4-8 Hz Frequency"]
    J --> K["Thalamocortical Synchrony
Network Coordination"]
    
    L["GluN2B Positive Modulator
Therapeutic Intervention"] --> A
    L --> M["Enhanced NMDA Function
Prolonged Deactivation"]
    M --> N["Sustained Depolarization
Temporal Integration"]
    N --> K
    
    O["Neurodegeneration
Pathological State"] --> P["Reduced GluN2B Expression
Receptor Downregulation"]
    P --> Q["Disrupted Oscillations
Loss of Synchrony"]
    Q --> R["Cognitive Impairment
Functional Outcome"]

classDef normal fill:#4fc3f7
classDef therapeutic fill:#81c784
classDef pathology fill:#ef5350
classDef outcome fill:#ffd54f
classDef molecular fill:#ce93d8

class A,B,C,D,E,M,N normal
class L therapeutic
class O,P,Q pathology
class R outcome
class F,G,H,I,J,K molecular

GTEx v10 Brain Expression

JSON

Median TPM across 13 brain regions for GRIN2B from GTEx v10.

Dimension Scores

How to read this chart: Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential. The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength), green shows moderate-weight factors (safety, competition), and yellow shows supporting dimensions (data availability, reproducibility). Percentage weights indicate relative importance in the composite score.

6 citations 6 with PMID Validation: 75% 3 supporting / 3 opposing

✓ For (3)

No supporting evidence

No opposing evidence

(3) Against ✗

High Medium Low

Evidence Matrix — sortable by strength/year, click Abstract to expand

Evidence Types

MECH 2CLIN 1GENE 3EPID 0

Claim	Stance	Category	Source	Strength ↕	Year ↕	Quality ↕	PMIDs	Abstract
Molecular mechanism of ligand gating and opening o…	Supporting	GENE	Nature	-	2024	-	PMID:39085540	-
Trans-synaptic molecular context of NMDA receptor …	Supporting	MECH	Nat Commun	-	2025	-	PMID:40796745	-
Mechanism of conductance control and neurosteroid …	Supporting	GENE	Nature	-	2025	-	PMID:41162707	-
NMDA receptors mediate synaptic depression in amyl…	Opposing	MECH	-	-	-	-	PMID:30352630	-
Epigenetics in Learning and Memory.	Opposing	GENE	Subcell Biochem	-	2025	-	PMID:39820860	-
Therapeutic potential of N-methyl-D-aspartate rece…	Opposing	CLIN	Neuropsychophar…	-	2024	-	PMID:37369776	-

Legacy Card View — expandable citation cards

✓ Supporting Evidence 3

Molecular mechanism of ligand gating and opening of NMDA receptor.

Nature · 2024 · PMID:39085540

Trans-synaptic molecular context of NMDA receptor nanodomains.

Nat Commun · 2025 · PMID:40796745

Mechanism of conductance control and neurosteroid binding in NMDA receptors.

Nature · 2025 · PMID:41162707

✗ Opposing Evidence 3

NMDA receptors mediate synaptic depression in amyloid models, suggesting NMDA enhancement could worsen dysfunc…▼

NMDA receptors mediate synaptic depression in amyloid models, suggesting NMDA enhancement could worsen dysfunction rather than improve it

PMID:30352630

Epigenetics in Learning and Memory.

Subcell Biochem · 2025 · PMID:39820860

Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.

Neuropsychopharmacology · 2024 · PMID:37369776

Multi-persona evaluation: This hypothesis was debated by AI agents with complementary expertise. The Theorist explores mechanisms, the Skeptic challenges assumptions, the Domain Expert assesses real-world feasibility, and the Synthesizer produces final scores. Expand each card to see their arguments.

Hypothesis Debate | 6 rounds | 2026-04-27 | View Analysis

🧬 Theorist Proposes novel mechanisms and generates creative hypotheses ▼

Mechanistic Analysis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PVALB in Early MCI

Critical Evaluation of Mechanistic Rationale

1. Foundational Claim: PV+ Interneurons as Gamma Pacemakers

The hypothesis correctly identifies parvalbumin-positive (PV+) fast-spiking interneurons as critical for gamma oscillation generation in hippocampal CA1. This is well-supported by extensive literature:

Buzsáki & Wang (2012) established the "interneuron network gamma" (ING) mechanism where PV+ cells synchronize through electrical coupling and rebound excitation
**Cardin et a

🔍 Skeptic Identifies weaknesses, alternative explanations, and methodological concerns ▼

Rigorous Skeptic's Critique: tFUS + 40Hz Gamma Entrainment Targeting PVALB in Early MCI

1. Weakest Assumptions

A. Mechanistic Specificity of tFUS → Ion Channel Cascade

Critical flaw: The hypothesis claims tFUS directly activates Nav1.1, Cav2.1, Cav1.3, Piezo1, and TREK-1 to trigger a specific molecular cascade. This assumes:

Mechanical forces from tFUS can selectively activate voltage-gated ion channels (designed for electrical, not mechanical, stimuli)

The downstream CaMKII → AMPA receptor phosphorylation occurs specifically in PV+ interneurons

This cascade is suff

🎯 Domain Expert Assesses practical feasibility, druggability, and clinical translation ▼

Translational Feasibility Assessment

Hypothesis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PV+ Interneuron Dysfunction in Early MCI

1. Target Druggability and Accessibility Assessment

Target Identification:

PVALB encodes parvalbumin, a calcium-binding protein that defines a distinct GABAergic interneuron subclass
PVALB itself is not directly druggable—it is a structural protein, not an enzyme or receptor
The actual functional target is PV+ interneuron activity and resulting 40Hz gamma oscillations

Accessibility with Existing Tools:

⚖ Synthesizer Integrates perspectives and produces final ranked assessments ▼

Synthesized Assessment: Closed-Loop tFUS with 40Hz Gamma Entrainment for Early MCI

Five-Dimensional Scoring

| Dimension | Score | Rationale |
|-----------|-------|-----------|
| Mechanistic Plausibility | 0.82 | The PV+ interneuron → gamma oscillation link is robustly established (Cardin et al., PMID:19339603; Buzsáki & Wang, 2012). However, the hypothesis overstates mechanistic precision by claiming direct activation of specific voltage-gated channels (Nav1.1, Cav2.1, Cav1.3) via tFUS. Evidence for mechanosensitive activation of these channels remains indirect. |
| **Evidence Str

Price History

7d Trend

↗

Rising

7d Momentum

▲ 3.7%

Volatility

Low

0.0078

Events (7d)

Clinical Trials (8) Relevance: 42%

0
Active

0
Completed

1,633
Total Enrolled

PHASE1
Highest Phase

The Effects of a Novel NMDA NR2B-Subtype Selective Antagonist, EVT 101, on Brain Function PHASE1

COMPLETED · NCT00526968 · Evotec Neurosciences GmbH

19 enrolled · 2007-09 · → 2007-12

The purpose of this study is to investigate the neurophysiological changes following single doses of EVT 101 using fMRI during rest and during cognitive tasks in young healthy male subjects.

Human Volunteers

EVT 101 EVT 101 placebo

The Dortmund Vital Study: Impact of Biological and Lifestyle Factors on Cognitive Performace and Work Ability N/A

ACTIVE_NOT_RECRUITING · NCT05155397 · Technical University of Dortmund

627 enrolled · 2016-04 · → 2035-12

The goal of the Dortmund Vital Study is to validate previous hypotheses and to generate and validate new hypotheses about the relationship of ageing, working conditions, genetic makeup, stress, metabo

Age-related Cognitive Decline

DL-3-n-butylphthalide Treatment in Patients With Mild to Moderate Alzheimer's Disease Already Receiving Donepezil N/A

COMPLETED · NCT02711683 · First Affiliated Hospital Xi'an Jiaotong University

92 enrolled · 2016-03 · → 2019-12

Alzheimer's disease (AD) is the commonest cause of dementia. There is no effective treatment to cure the disease. Cholinesterase inhibitors, such as donepezil, are widely recommended to patients with

Alzheimer's Disease

DL-3-n-butylphthalide Donepezil

A Study of an Investigational Drug to See How it Affects the People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) Compared to an Approved Drug Used to Treat People With Parkinson's Disease Complicated by Motor Fluctuations ("OFF" Episodes) PHASE3

COMPLETED · NCT03391882 · Sumitomo Pharma America, Inc.

113 enrolled · 2018-12-19 · → 2021-08-11

A study of an investigational drug to see how it affects the people with Parkinson's Disease complicated by motor fluctuations ("OFF" Episodes) compared to an approved drug used to treat people with P

Motor OFF Episodes Associated With Parkinson's Disease

APL-130277 subcutaneous apomorphine

Protective Anesthesiological Management Procedure Imposes Control on Respiratory Comlications NA

UNKNOWN · NCT06282003 · Masa Kontic

53 enrolled · 2023-10-10 · → 2024-06-30

Anesthetic effects, surgery, and invasive mechanical intubation can impair respiratory function during general anesthesia. The risk factors for postoperative pulmonary complications (PPCs) include the

Well-Being, Psychological

The procedure of protective lung ventilation

Long-Term Safety of PRC-063 in Adolescents and Adults With ADHD PHASE3

COMPLETED · NCT02168127 · Rhodes Pharmaceuticals, L.P.

360 enrolled · 2014-05 · → 2015-05

The purpose of this six month, open-label study is to evaluate the long-term safety and efficacy of PRC-063 in adults and adolescents with ADHD.

ADHD

Drug: PRC-063 PRC-063

5-Aminolevulinic Acid (5-ALA) to Enhance Visualization of Malignant Tumor N/A

COMPLETED · NCT02632370 · Constantinos Hadjipanayis

69 enrolled · 2016-05 · → 2018-12-31

In support of the US marketing application for 5-ALA, this single arm trial is being conducted to establish the efficacy and safety of Gliolan® (5-ALA) in patients with newly diagnosed or recurrent ma

Malignant Gliomas

Gliolan® Fluorescence-Guided Surgery

Magnetic Resonance Imaging of Brain Development in Autism N/A

UNKNOWN · NCT00449566 · UMC Utrecht

300 enrolled · 2006-01

The purpose of this study is to investigate brain development in autism by longitudinally assessing children with autism, as well as typically developing controls, using advanced MR techniques. We wil

Autism

📚 Cited Papers (6)

NMDA receptors mediate synaptic depression, but not spine loss in the dentate gyrus of adult amyloid Beta (Aβ) overexpressing mice.

Acta neuropathologica communications (2019) · PMID:30352630

No extracted figures yet

Therapeutic potential of N-methyl-D-aspartate receptor modulators in psychiatry.

Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology (2023) · PMID:37369776

No extracted figures yet

Molecular mechanism of ligand gating and opening of NMDA receptor.

Nature (2024) · PMID:39085540

No extracted figures yet

Epigenetics in Learning and Memory.

Sub-cellular biochemistry (2025) · PMID:39820860

No extracted figures yet

Paper:40796745

No extracted figures yet

Mechanism of conductance control and neurosteroid binding in NMDA receptors.

Nature (2025) · PMID:41162707

No extracted figures yet

📅 Citation Freshness Audit

Freshness score = exp(-age×ln2/5): halves every 5 years. Green >0.6, Amber 0.3–0.6, Red <0.3.

No citation freshness data yet. Export bibliography — run scripts/audit_citation_freshness.py to populate.

📙 Related Wiki Pages (0)

No wiki pages linked to this hypothesis yet.

࢐ Browse all wiki pages

📓 Linked Notebooks (1)

📓 Circuit-level neural dynamics in neurodegeneration — Analysis Notebook

CI-generated notebook stub for analysis SDA-2026-04-03-26abc5e5f9f2. Analyze circuit-level changes in neurodegeneration using Allen Institute Neural Dynamics data. Focus on: (1) hippocampal circuit di …

→ Browse all notebooks

⚔ Arena Performance

No arena matches recorded yet. Browse Arenas

Origin

mutate · gen 3

parent: h-var-e2b5a7e7db

→ Browse all arenas & tournaments

📊 Resource Economics & ROI

Moderate Efficiency Resource Efficiency Score

0.73

48.2th percentile (776 hypotheses)

Tokens Used

9,494

KG Edges Generated

159

Citations Produced

Cost Ratios

Cost per KG Edge

88.73 tokens

Lower is better (baseline: 2000)

Cost per Citation

499.68 tokens

Lower is better (baseline: 1000)

Cost per Score Point

13167.82 tokens

Tokens / composite_score

Score Impact

Efficiency Boost to Composite

+0.073

10% weight of efficiency score

Adjusted Composite

0.637

How Economics Pricing Works

Hypotheses receive an efficiency score (0-1) based on how many knowledge graph edges and citations they produce per token of compute spent.

High-efficiency hypotheses (score >= 0.8) get a price premium in the market, pulling their price toward $0.580.

Low-efficiency hypotheses (score < 0.6) receive a discount, pulling their price toward $0.420.

Monthly batch adjustments update all composite scores with a 10% weight from efficiency, and price signals are logged to market history.

📋 Reviews View all →

Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.

💬 Discussion

No DepMap CRISPR Chronos data found for GRIN2B.

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for GRIN2B →

Loading history…

⚖️ Governance History

No governance decisions recorded for this hypothesis.

Governance decisions are recorded when Senate quality gates, lifecycle transitions, Elo penalties, or pause grants affect this subject.

Browse all governance decisions →

KG Entities (130)

40Hz gamma entrainment APOE APOE4 APP AQP4 Alzheimer's disease Alzheimer's disease pathology BDNF CA1 CA3 CAMK2A CDK5 CHAT CSF1R CaMKII CaMKII_protein Closed-loop tACS EC layer II SST interneurons Entorhinal cortex layer II GABAergic interneuron networks

Related Hypotheses

GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance

Score: 0.964 | neuroscience

Thalamocortical Synchrony Restoration via NMDA Modulation

Score: 0.743 | neuroscience

Cortico-Striatal Synchrony Restoration via NMDA Modulation

Score: 0.723 | neuroscience

Subtle NMDAR Inhibition Attenuates Excitotoxicity-Driven Tau Release from Hypersynchronized Circuits

Score: 0.620 | neurodegeneration

Ketone-Primed Thalamocortical Enhancement of Glymphatic Tau Clearance

Score: 0.565 | neuroscience

Estimated Development

Estimated Cost

Timeline

2.0 years

🧪 Falsifiable Predictions (2)

2 total 0 confirmed 0 falsified

IF thalamocortical gamma oscillations are optogenetically enhanced in a tauopathy mouse model (e.g., rTg4510), THEN microglial morphological score and CD206/CD68 ratio will increase significantly within 4 weeks compared to controls, AND tau propagation from thalamus to somatosensory cortex will be reduced by >30% as measured by longitudinal in vivo tau-PET or immunohistochemistry.

pending conf: 0.55

Expected outcome: Increased homeostatic microglial marker expression (CD206+/Iba1+ ratio) and decreased pro-inflammatory markers (CD16/32, TNF-alpha) in thalamic regions; 30-50% reduction in phosphorylated tau accumulation in thalamocortical projection zones.

Falsified by: No significant change in microglial phenotype markers (CD206/CD68 ratio change <15%), OR tau pathology burden increases or remains unchanged in the thalamocortical pathway despite restored gamma synchrony.

Method: Optogenetic entrainment of thalamic gamma oscillations (ArchT or ChrimsonR expression in anterior thalamic nucleus) in 6-month-old rTg4510 mice; longitudinal two-photon imaging of microglial morphology; post-mortem stereological quantification of tau pathology (AT8, MC1) in thalamocortical circuits; pharmacogenetic microglial depletion controls (CX3CR1-CreER;DTA).

IF microglial GluN2B (GRIN2B) is selectively enhanced via pharmacogenetic activation (e.g., DREADD-hM3Dq under Cx3cr1 promoter) WITHOUT thalamocortical synchrony restoration, THEN tau internalization capacity will increase by >40% in primary microglial cultures derived from P301S mice within 72 hours, AND hippocampal tau spreading to entorhinal cortex will be reduced in vivo.

pending conf: 0.48

Expected outcome: 40-60% increase in tau-eGFP or tau-RFP internalization in cultured microglia from GRIN2B-enhanced cells; reduced seeding activity in ex vivo bioassay; 25% reduction in entorhinal cortex tau burden in vivo.

Falsified by: Enhanced microglial GluN2B does NOT increase tau clearance capacity (internalization unchanged or <20% increase), OR tau propagation continues unabated despite microglial GluN2B activation, indicating thalamocortical synchrony is a required upstream driver.

Method: Primary microglial cultures from Cx3cr1-Cre;GRIN2B-cOE or hM3Dq-x-P301S mice; confocal microscopy quantification of tau-eGFP internalization over 72 hours; ex vivo FRET-based tau seeding assay; stereotaxic injection of tau seeds into hippocampus with concurrent CNO-mediated microglial GluN2B activation; longitudinal monitoring of tau spreading via in vivo imaging or endpoint histology.

Knowledge Subgraph (138 edges)

▸ Show 10 more

PVALB→Alzheimer's diseaseSST→alzheimer_s_diseasePVALB→alzheimer_s_diseaseBDNF→alzheimer_s_diseasePVALB/SST→neuroscienceSST interneurons→Entorhinal cortex layer IIGamma oscillation disruption→Alzheimer's diseaseamyloid accumulation→PV+ interneuron dysfunctionamyloid accumulation→PV+ interneuronsSST→Alzheimer's disease

biomarker for (1)

gamma collapse→early MCI

catalyzes (1)

choline_acetyltransferase→cholinergic_signaling

causal extracted (2)

sess_ext_h-var-58e76ac310_20260428_050154→processedsess_ext_h-var-3b982ec3d2_20260428_045746→processed

causes (8)

tau pathology→SST interneuron dysfunctionSST interneuron dysfunction→accelerated tau propagationSST interneuron dysfunction→gamma desynchronizationoptogenetic gamma stimulation→tau pathology reductionTau pathology→SST interneuron dysfunction

▸ Show 3 more

Tau pathology→Tau propagationPV+ interneuron dysfunction→gamma collapsegamma collapse→hippocampal-cortical disconnect

causes (CaMKII enhancement promotes dendrite ramification ) (1)

CaMKII→dendrite ramification

causes (CaMKII-dependent process that promotes spine gener) (1)

CaMKII→spine generation

causes (NMDA receptors mediate synaptic depression in amyl) (1)

NMDA receptors→synaptic depression

causes (VIP interneuron-mediated disinhibition allows pyra) (1)

VIP interneuron stimulation→pyramidal cell disinhibition

causes (loss of natural sensory input leads to degeneratio) (1)

natural sensory input loss→cholinergic circuit degeneration

causes (optogenetic activation selectively restores gamma ) (1)

optogenetic activation of PV interneurons→gamma oscillation restoration

causes (optogenetic activation selectively restores theta ) (1)

optogenetic activation of SST interneurons→theta oscillation restoration

causes (selective modulation of GluN2B-containing NMDA rec) (1)

GluN2B modulation→thalamocortical synchronization

causes (selective noradrenaline depletion exacerbates syna) (1)

noradrenaline depletion→synaptic deficits

causes (specifically disrupt parvalbumin-positive interneu) (1)

amyloid-β oligomers→PV interneurons

causes (specifically disrupt somatostatin-positive interne) (1)

amyloid-β oligomers→SST interneurons

causes (tau pathology spreads from locus coeruleus to hipp) (1)

tau pathology→hippocampal circuit dysfunction

co associated with (19)

BDNF→SSTCAMK2A→CHATCAMK2A→VIPCAMK2A→GRIN2BCHAT→VIP

▸ Show 14 more

CHAT→GRIN2BCAMK2A→MAPTCHAT→MAPTMAPT→VIPGRIN2B→MAPTBDNF→PVALBGRIN2B→VIPBDNF→CA3BDNF→CA1CAMK2A→PVALB/SSTCHAT→PVALB/SSTGRIN2B→PVALB/SSTMAPT→PVALB/SSTPVALB/SST→VIP

co discussed (14)

RAB5→TREM2RAB7→TREM2APP→GAD1GAD1→PSEN1BDNF→PSD95

▸ Show 9 more

APOE4→BDNFBDNF→CSF1RBDNF→TREM2HDAC→PSD95APP→PSD95AQP4→MAPTAPOE→TFEBCDK5→MAPKAQP4→TREM2

disrupts (1)

MAPT→hippocampal_circuit

dysfunction causes (1)

thalamocortical_circuit→cognitive_impairment

encodes (4)

CHAT→choline_acetyltransferaseGRIN2B→GluN2B_receptorMAPT→tau_proteinCAMK2A→CaMKII_protein

enhances (2)

gamma oscillations at 40Hz→glymphatic clearancegamma oscillations (40Hz)→glymphatic clearance

expressed in (3)

VIP→VIP_interneuronsPVALB→PV_interneuronsSST→SST_interneurons

generates (4)

PV_interneurons→gamma_oscillationsSST_interneurons→theta_oscillationsPVALB→gamma_oscillationSST→theta_oscillation

implicated in (7)

PVALB→neurodegenerationh-cd60e2ec→neuroscienceh-f8316acf→neuroscienceh-23b94ed8→neuroscienceh-62c78d8b→neuroscience

▸ Show 2 more

h-a635d4e5→neuroscienceh-7110565d→neuroscience

inhibits (1)

tACS→EC layer II SST interneurons

investigated in (4)

diseases-psp→h-var-6612521a02diseases-corticobasal-syndrome→h-var-9c0368bb70diseases-ftd→h-var-3b982ec3d2diseases-vascular-cognitive-impairment→h-var-6612521a02

involved in (3)

SST→gabaergic_interneuron_networksPVALB→prefrontal_inhibitory_circuitsBDNF→hippocampal_neurogenesis_and_synaptic_plasticity

modulates (12)

VIP_interneurons→default_mode_networkGluN2B_receptor→thalamocortical_circuitGRIN2B→thalamocortical_synchronygamma-frequency stimulation→tau pathologyGamma frequency stimulation→Alzheimer's disease pathology

▸ Show 7 more

Optogenetics→SST interneuron modulationClosed-loop tACS→Gamma entrainmentPV+ interneuron activity→excitatory transmissionclosed-loop tFUS→PV+ interneuron activitygamma oscillations (40Hz)→microglial phagocytosisgamma oscillations (40Hz)→excitatory transmissiontranscranial focused ultrasound (tFUS)→deep brain structures

participates in (2)

SST→GABAergic interneuron networksPVALB→Prefrontal inhibitory circuits

promotes (1)

CaMKII_protein→synaptic_plasticity

propagates through (1)

tau_protein→locus_coeruleus_hippocampus_pathway

regulates (5)

SST→gamma_oscillationSST interneurons→gamma oscillationsSST interneurons→Gamma oscillationsgamma oscillations (40Hz)→hippocampal-cortical connectivityPVALB→PV+ interneurons

studied in (3)

SST→neurosciencePVALB→neuroscienceBDNF→neuroscience

targets (2)

h-a635d4e5→VIPBDNF→Alzheimer's disease

therapeutic target (2)

SST→Alzheimer's diseasePVALB→Alzheimer's disease

therapeutic target for (2)

40Hz gamma entrainment→early MCIPV+ interneuron activity→Alzheimer's disease

Mechanism Pathway for GRIN2B

Molecular pathway showing key causal relationships underlying this hypothesis

graph TD
    GRIN2B["GRIN2B"] -->|modulates| thalamocortical_synchrony["thalamocortical_synchrony"]
    GRIN2B_1["GRIN2B"] -->|associated with| neuroscience["neuroscience"]
    GRIN2B_2["GRIN2B"] -->|encodes| GluN2B_receptor["GluN2B_receptor"]
    CAMK2A["CAMK2A"] -->|co associated with| GRIN2B_3["GRIN2B"]
    CHAT["CHAT"] -->|co associated with| GRIN2B_4["GRIN2B"]
    GRIN2B_5["GRIN2B"] -->|co associated with| MAPT["MAPT"]
    GRIN2B_6["GRIN2B"] -->|co associated with| VIP["VIP"]
    GRIN2B_7["GRIN2B"] -->|co associated with| PVALB_SST["PVALB/SST"]
    style GRIN2B fill:#ce93d8,stroke:#333,color:#000
    style thalamocortical_synchrony fill:#81c784,stroke:#333,color:#000
    style GRIN2B_1 fill:#ce93d8,stroke:#333,color:#000
    style neuroscience fill:#ef5350,stroke:#333,color:#000
    style GRIN2B_2 fill:#ce93d8,stroke:#333,color:#000
    style GluN2B_receptor fill:#4fc3f7,stroke:#333,color:#000
    style CAMK2A fill:#ce93d8,stroke:#333,color:#000
    style GRIN2B_3 fill:#ce93d8,stroke:#333,color:#000
    style CHAT fill:#ce93d8,stroke:#333,color:#000
    style GRIN2B_4 fill:#ce93d8,stroke:#333,color:#000
    style GRIN2B_5 fill:#ce93d8,stroke:#333,color:#000
    style MAPT fill:#ce93d8,stroke:#333,color:#000
    style GRIN2B_6 fill:#ce93d8,stroke:#333,color:#000
    style VIP fill:#ce93d8,stroke:#333,color:#000
    style GRIN2B_7 fill:#ce93d8,stroke:#333,color:#000
    style PVALB_SST fill:#ce93d8,stroke:#333,color:#000

Predicted Protein Structure

🔮 GRIN2B — AlphaFold Prediction Q13224 Click to expand 3D viewer

AI-predicted structure from AlphaFold | Powered by Mol* | Rotate: click+drag | Zoom: scroll | Reset: right-click

Source Analysis

Circuit-level neural dynamics in neurodegeneration

neuroscience | 2026-04-03 | completed

Community Feedback

0 0 upvotes · 0 downvotes

💬 0 comments ⚠ 0 flags ✏ 0 edit suggestions

No comments yet. Be the first to comment!

View all feedback (JSON)

Same Analysis (5)

GluN2B-Mediated Thalamocortical Control of Glymphatic Tau Clearance

Score: 0.96 · GRIN2B

Closed-loop transcranial focused ultrasound targeting EC-II SST intern

Score: 0.96 · SST

Closed-loop optogenetic targeting PV interneurons to restore theta-gam

Score: 0.95 · PVALB

Closed-loop transcranial focused ultrasound to restore hippocampal gam

Score: 0.91 · CCK

Gamma entrainment therapy to restore hippocampal-cortical synchrony

Score: 0.90 · SST

→ View all analysis hypotheses

GluN2B-Mediated Microglial Activation and Tau Propagation

Description

Mechanistic Overview

Mechanistic Overview

Molecular and Cellular Rationale

Evidence Supporting the Hypothesis

Contradictory Evidence, Caveats, and Failure Modes

Clinical and Translational Relevance

Experimental Predictions and Validation Strategy

Decision-Oriented Summary

Curated Mechanism Pathway

GTEx v10 Brain Expression

Dimension Scores

✓ Supporting Evidence 3

✗ Opposing Evidence 3

Mechanistic Analysis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PVALB in Early MCI

Critical Evaluation of Mechanistic Rationale

1. Foundational Claim: PV+ Interneurons as Gamma Pacemakers

Rigorous Skeptic's Critique: tFUS + 40Hz Gamma Entrainment Targeting PVALB in Early MCI

1. Weakest Assumptions

A. Mechanistic Specificity of tFUS → Ion Channel Cascade

Translational Feasibility Assessment

Hypothesis: Closed-Loop tFUS with 40Hz Gamma Entrainment Targeting PV+ Interneuron Dysfunction in Early MCI

1. Target Druggability and Accessibility Assessment

Synthesized Assessment: Closed-Loop tFUS with 40Hz Gamma Entrainment for Early MCI

Five-Dimensional Scoring

Price History

Clinical Trials (8) Relevance: 42%

📚 Cited Papers (6)

📅 Citation Freshness Audit

📙 Related Wiki Pages (0)

📓 Linked Notebooks (1)

⚔ Arena Performance

Origin

🔄 Related Hypotheses

Same Analysis (5)

🧬 Same Target Gene / Disease (8)

📊 Resource Economics & ROI

Cost Ratios

Score Impact

How Economics Pricing Works

📋 Reviews View all →

💬 Discussion

⚖️ Governance History

KG Entities (130)

Related Hypotheses

Estimated Development

🧪 Falsifiable Predictions (2)

Knowledge Subgraph (138 edges)

accelerates (1)

activates (5)

associated with (15)

biomarker for (1)

catalyzes (1)

causal extracted (2)

causes (8)

causes (CaMKII enhancement promotes dendrite ramification ) (1)

causes (CaMKII-dependent process that promotes spine gener) (1)

causes (NMDA receptors mediate synaptic depression in amyl) (1)

causes (VIP interneuron-mediated disinhibition allows pyra) (1)

causes (loss of natural sensory input leads to degeneratio) (1)

causes (optogenetic activation selectively restores gamma ) (1)

causes (optogenetic activation selectively restores theta ) (1)

causes (selective modulation of GluN2B-containing NMDA rec) (1)

causes (selective noradrenaline depletion exacerbates syna) (1)

causes (specifically disrupt parvalbumin-positive interneu) (1)

causes (specifically disrupt somatostatin-positive interne) (1)

causes (tau pathology spreads from locus coeruleus to hipp) (1)

co associated with (19)

co discussed (14)

disrupts (1)

dysfunction causes (1)

encodes (4)

enhances (2)

expressed in (3)

generates (4)

implicated in (7)

inhibits (1)

investigated in (4)

involved in (3)